NCT01228760 - A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Prostate Neoplasms

Interventions

DRUG

ASG-5ME

Trial Locations (4)

Memorial Sloan Kettering Cancer Center, New York

The Sidney Kimmel Comprehensive Cancer Center, Baltimore

The Karmanos Cancer Institute, Detriot

University of Wisconsin Madison, Carbone Cancer Center, Madison